Name in SEC filings: INCYTE CORP
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| INCA033989 | /data readout | Phase 1 | second half of 2026 | EX-99.1 · |
| INCA33890 | Topline/data readout | Phase 1 | second half of 2026 | 10-Q · |
| INCB160058 | Topline/data readout | Phase 1 | second half of 2026 | 10-Q · |
| axatilimab + ruxolitinib | Topline/data readout | Stage not stated | second half of 2026 | 10-Q · |
| povorcitinib | Topline/data readout | Phase 2 | second half of 2026 | EX-99.1 · |
| povorcitinib | Topline/data readout | Phase 3 | fourth quarter of 2026 | EX-99.1 · |
| povorcitinib | Topline/data readout | Stage not stated | second half of 2026 | 10-Q · |
| ruxolitinib cream | Topline/data readout | Phase 3 | fourth quarter of 2026 | EX-99.1 · |
| INCB161734 + chemotherapy | Topline/data readout | Stage not stated | second half of 2026 | 10-Q · |
Source: ORION, orionbiotechai.com/company/INCY, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/INCY
INCA033989 · Topline/data readout · second half of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $11,200,000,000 · as of · SEC filing
Data from the Phase 1 cohort evaluating INCA033989 as a monotherapy and in combination with ruxolitinib in treatment naïve MF patients are anticipated in the second half of 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $11,200,000,000 · as of · SEC filing
Additional data from the ongoing Phase 1 study evaluating INCA33890 in combination with bevacizumab and/or chemotherapy in patients with solid tumors is anticipated in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $11,200,000,000 · as of · SEC filing
Results from the Phase 1 trial evaluating INCB160058 in MPN patients with a JAK2V617F mutation are anticipated in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Not stated
Public float: $11,200,000,000 · as of · SEC filing
ruxolitinib in patients with newly diagnosed chronic GVHD is ongoing, with results anticipated in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $11,200,000,000 · as of · SEC filing
Topline data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutfourth quarter of 2026
Stage: Phase 3SEC filing · “Phase 3”
Public float: $11,200,000,000 · as of · SEC filing
Data from the Phase 3 studies (STOP-PN1 and STOP-PN2) evaluating povorcitinib in patients with moderate to severe prurigo nodularis (PN) are anticipated in the fourth quarter of 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Not stated
Public float: $11,200,000,000 · as of · SEC filing
additional data from STOP-V1 and STOP-V2 in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutfourth quarter of 2026
Stage: Phase 3SEC filing · “Phase 3”
Public float: $11,200,000,000 · as of · SEC filing
Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Not stated
Public float: $11,200,000,000 · as of · SEC filing
treatment in patients with metastatic PDAC is anticipated in the second half of 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| axatilimab + ruxolitinibClinical results | second half of 2026“ruxolitinib in patients with newly diagnosed chronic GVHD is ongoing, with results anticipated in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| INCA033989Clinical results | second half of 2026“Data from the Phase 1 cohort evaluating INCA033989 as a monotherapy and in combination with ruxolitinib in treatment naïve MF patients are anticipated in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| INCA33890Clinical results | second half of 2026“Additional data from the ongoing Phase 1 study evaluating INCA33890 in combination with bevacizumab and/or chemotherapy in patients with solid tumors is anticipated in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| INCB161734 + chemotherapyClinical results | second half of 2026“treatment in patients with metastatic PDAC is anticipated in the second half of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | second half of 2026“Topline data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | fourth quarter of 2026“Data from the Phase 3 studies (STOP-PN1 and STOP-PN2) evaluating povorcitinib in patients with moderate to severe prurigo nodularis (PN) are anticipated in the fourth quarter of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | second half of 2026“additional data from STOP-V1 and STOP-V2 in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ruxolitinib creamClinical results | fourth quarter of 2026“Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| axatilimab + ruxolitinibClinical results | second half of 2026“ruxolitinib in patients with newly diagnosed chronic GVHD is ongoing, with results anticipated in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| axatilimab + ruxolitinibClinical results | second half of 2026“Data from the Phase 2 trial evaluating axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic GVHD are anticipated in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| INCA033989Clinical results | second half of 2026“Data from the cohort evaluating INCA033989 and INCA033989 in combination with ruxolitinib in treatment naïve MF patients are anticipated in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| INCA33890Clinical results | second half of 2026“Additional data from the ongoing Phase 1 study evaluating INCA33890 in combination with bevacizumab and/or chemotherapy in patients with solid tumors is expected in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| INCA33890Clinical results | second half of 2026“Additional data from the ongoing Phase 1 study evaluating INCA33890 in combination with bevacizumab and/or chemotherapy in patients with solid tumors is expected in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| INCB160058Clinical results | second half of 2026“Results from the Phase 1 trial evaluating INCB160058 in MPN patients with a JAK2V617F mutation are anticipated in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | second half of 2026“data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | second half of 2026“additional data from STOP-V1 and STOP-V2 in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ruxolitinib creamClinical results | fourth quarter of 2026“topline results anticipated in the fourth quarter of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ruxolitinib creamClinical results | fourth quarter of 2026“results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| axatilimab + ruxolitinibClinical results | early 2027“ruxolitinib in patients with newly diagnosed chronic GVHD is ongoing, with results anticipated in early 2027” Filed · 10-K | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| INCB160058Clinical results | second half of 2026“Results from the Phase 1 trial evaluating INCB160058 in MPN patients with a JAK2V617F mutation are anticipated in the second half of 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | second half of 2026“data from the Phase 2 proof-of-concept trial for povorcitinib in asthma are anticipated in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| ruxolitinib creamClinical results | fourth quarter of 2026“topline results anticipated in the fourth quarter of 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| ruxolitinib creamClinical results | fourth quarter of 2026“results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| povorcitinibClinical results | 2026“data from the Phase 2 proof-of-concept trial in asthma, are anticipated in 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| povorcitinibClinical results | second half of 2025“data in asthma are anticipated in the second half of 2025” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| povorcitinibClinical results | 2026“Phase 3 data are anticipated in 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| povorcitinibClinical results | second half of 2025“data in asthma are anticipated in the second half of 2025” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| povorcitinibClinical results | second half of 2025“data in asthma are anticipated in the second half of 2025” Filed · 10-K | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| povorcitinibClinical results | second half of 2025“data in asthma are anticipated in the second half of 2025” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| povorcitinibClinical results | second half of 2025“data in asthma are anticipated in the second half of 2025” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for INCY. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See INCY in the calendar · Review labels and methodology